MARKET

IBIO

IBIO

Ibio
NASDAQ
1.930
+0.220
+12.87%
After Hours: 1.900 -0.03 -1.55% 19:46 12/31 EST
OPEN
1.700
PREV CLOSE
1.710
HIGH
1.950
LOW
1.700
VOLUME
1.01M
TURNOVER
--
52 WEEK HIGH
6.89
52 WEEK LOW
0.5562
MARKET CAP
43.40M
P/E (TTM)
-1.3425
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IBIO last week (1222-1226)?
Weekly Report · 12/29/2025 09:57
Ibio, RLMD, SEE, OLLI, Invivyd Trending With Analysts
TipRanks · 12/27/2025 09:00
Weekly Report: what happened at IBIO last week (1215-1219)?
Weekly Report · 12/22/2025 09:57
iBio initiated with an Outperform at LifeSci Capital
TipRanks · 12/18/2025 13:41
Analysts Conflicted on These Healthcare Names: Ibio (IBIO), Q32 Bio (QTTB) and Progyny (PGNY)
TipRanks · 12/18/2025 13:10
EcoR1 Capital Reports 9.9% Passive Stake In IBio As Of Dec 10
Benzinga · 12/17/2025 22:49
ECOR1 CAPITAL LLC REPORTS 9.9% PASSIVE STAKE IN IBIO INC AS OF DEC 10- SEC FILING
Reuters · 12/17/2025 22:45
Weekly Report: what happened at IBIO last week (1208-1212)?
Weekly Report · 12/15/2025 10:02
More
About IBIO
iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. Its pre-clinical pipeline of immuno-oncology targets the treatment of solid tumors, glioblastoma, head, and neck cancers. Its pipeline includes IBIO-101, TROP-2 x CD3, MUC16, EGFRvIII, CCR8, and Target 5. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.

Webull offers Ibio Inc stock information, including NASDAQ: IBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IBIO stock methods without spending real money on the virtual paper trading platform.